Podcasts about mounjaro

Tired of ADHD strategies that don't work? Start with this training: Stop Trying to “Fix” Your ADHD. You're Not Broken: https://programs.tracyotsuka.com/sign-up_____About one in nine adults is on a GLP-1 right now. And women with ADHD kept telling me the exact same thing after starting GLP-1 medications: they expected to lose weight, but they did not expect their brains to feel different.The brain fog lifted. The food noise got quieter. Energy felt steadier. Emotional reactions became easier to interrupt. For some, inflammation, pain, bloating, cravings, and compulsive behaviors changed too.So I brought back Dr. Kalin Johnson to tell us whether there is real science behind that or whether we are getting ahead of the evidence. Kalin is a licensed clinical pharmacist, functional medicine wellness coach, and patient advocate who runs a concierge whole-person care practice for high-achieving, high-masking neurodivergent adults. She is also queer, ADHD, autistic, and living with hypermobile Ehlers-Danlos Syndrome, and this is her fourth time on the show.In this episode, Kalin and I get into how GLP-1 receptors communicate across the gut, brain, pancreas, immune system, and vagus nerve, and why that matters for ADHD women. They also talk about food noise, brain fog, inflammation, metabolic health, emotional regulation, microdosing, side effects, muscle loss, access, and what the research still cannot tell us.ResourcesWebsite: https://www.kalinjohnson.comInstagram: https://www.instagram.com/kalinpharmdLinkedIn: https://www.linkedin.com/in/kalin-johnsonpharmdAnia Jastreboff, MD - Director of the Yale Obesity Research Center, principal investigator on many of the landmark trials for tirzepatide and retatrutide. If you watch only one thing, watch her Lincoln Center talk. https://medicine.yale.edu/profile/ania-jastreboffDr. Spencer Nadolsky - https://www.instagram.com/drnadolskyRocio Salas-Whalen MD - https://www.instagram.com/drsalaswhalenSend a Message: Your Name | Email | Message Explore more from me:

You've seen the ads. You've heard the buzz. But do you actually know what peptides are — or what they're doing inside your body? In this first episode of a three-part series, Jamie Preston sits down with Dr. Melissa Jones, a 25-year clinical pharmacist and VP at Your Health, to lay the foundation every patient and provider needs before entering the peptide conversation. Dr. Jones brings rare credibility to this space — she didn't come in as a believer, she came in as a scientist who was challenged to learn, and what she found changed how she practices. What you'll hear in this episode: Why insulin is a peptide — and why that means peptides have been in your medicine cabinet for years How BPC 157 and TB 500 work together to signal the body to heal — and the real patient stories behind that science Why GLP-1 medications like Mounjaro and Ozempic are peptides, and how they actually produce weight loss The difference between peptides and steroids (hint: one sends signals, one messes with your hormones) Why "research use only" labels are a red flag — and why compounding pharmacies matter more than you think What providers need to start asking patients right now Whether you're a patient who's been curious or a provider who's been hesitant, this episode gives you the grounded, evidence-informed starting point you've been looking for. Part two goes even deeper — but this is where it begins. www.YourHealth.Org

 Stay here for it. You'll like thisDownload your FREE Desi Calorie Calculator - https://desi-calculator.vercel.app/ [It's Free]--------LET'S CHAT 

You might think the win on a GLP-1 like Ozempic or Mounjaro is the number dropping on your scale, but I need you to ask a better question, not how much you're losing, but what kind. In some studies, 40 to 60% of the weight people lost on these drugs came from lean muscle, not fat, and that's a metabolic loss that costs you your strength and your ability to keep the weight off. These are the most powerful fat-loss tools we've ever had, but a tool without a protocol is just potential. Hit your protein and lift, or you're trading muscle for a number you'll spend years trying to earn back. CLICK HERE TO BECOME GARYS VIP!: https://bit.ly/4ai0Xwg Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKpCYMBIOTIKA: "BRECKACYM30" FOR 30% OFF: https://bit.ly/4tjyluP GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 - Intro of Show 00:22 - Weight loss vs fat loss 00:38 - What GLP-1 does in the body 01:02 - Semaglutide: the first generation 01:28 - Tirzepatide and the dual agonist 01:45 - Retatrutide and 24.2% body weight loss 02:20 - Why each added receptor works 02:38 - The hidden cost: protecting lean muscle 03:05 - 60% of weight loss from muscle 03:35 - The two-part fix: protein and training 04:05 - Protein targets and leucine-rich sources 04:30 - Resistance training and compound lifts 05:00 - Use the medication, do the work Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions.  Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation.  Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Cutting Edge #26 Are you currently taking a GLP-1 medication (like Ozempic, Wegovy, Mounjaro, or Zepbound) and planning for plastic surgery or general anesthesia? In this critical episode of The Cutting Edge Podcast, host Mel sits down with bariatric therapist Ashlyn Douglass-Barnes and board-certified plastic surgeon Dr. Omar Beidas to unpack the medical, psychological, and surgical risks every patient must know. If you are navigating weight loss surgery, post-bariatric skin removal, or GLP-1 therapy, this video explains why stopping your injection before surgery isn't optional—it could literally save your life.

July is the Saturday of summer. Life feels a little lighter, the rules feel looser, and for a minute, you can breathe before August shows up with its deadlines, resets, and Sunday scaries.As I'm getting ready for my birthday trip and trying to soak up the last bit of that July freedom, I've been thinking about how often two things can be true at the same time. I can love the life I've worked so hard to build and still feel overwhelmed. I can be proud of how far I've come in my weight and body image journey and still have days when it feels hard. I can appreciate my body and still want change.In this episode, we're talking about letting go of the all-or-nothing thinking that tells us we have to pick one truth, and making room for the messy, complicated reality of healing, growth, and actually living your life.Irresistible Links:Show Notes

Los fármacos análogos de GLP-1 (Ozempic, Wegovy, Mounjaro...) están revolucionando el tratamiento de la obesidad y el sobrepeso, pero hay una dimensión de la que se habla muy poco: el ruido mental (food noise) y el estigma social.En este episodio analizamos:¿Qué es el ruido mental alrededor de la comida? Cómo los pensamientos intrusivos constantes afectan a la relación con la alimentación y por qué el GLP-1 apaga ese "ruido".El juicio de la sociedad: Por qué se acusa injustamente de "hacer trampa" o de "falta de voluntad" a quienes recurren al tratamiento farmacológico.El abordaje integral: Por qué la medicación no es una varita mágica y necesita ir acompañada de reeducación nutricional, ejercicio de fuerza y apoyo psicológico para ser sostenible.Un episodio necesario para romper prejuicios y entender la obesidad desde la ciencia, la empatía y la salud.Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/comiendo-con-maria-nutricion--2497272/support.

If you or someone you know is on a GLP-1 medication like Ozempic, Wegovy, or Mounjaro and the results have plateaued, or the weight is starting to creep back, this episode has the explanation you have been looking for and it is probably not what your doctor told you. This week Susie breaks down exactly why these medications stop working for so many people, what is actually going wrong metabolically, and what to do about it instead of just increasing the dose. Then Leanne takes over for a genuinely useful segment on the Coles and Woolworths home brand products both dietitians buy every single week, which ones are just as good as the branded version, and which ones they would never swap out. In this episode: Why GLP-1 medications like Mounjaro, Ozempic, and Wegovy stop working: the two metabolic patterns Susie sees most commonly in her clients, and why increasing the dose is often exactly the wrong response Why dramatically reducing calorie intake without addressing muscle mass and exercise will always lead to a plateau, and the counterintuitive reason why eating a little more and reducing the dose can actually restart results Why muscular, active women are particularly vulnerable to GLP-1 plateaus, and how being in carbohydrate no man's land sabotages fat burning even when the medication is working properly Why these medications should never be given without dietitian support, and what to actually focus on if you want to come off them eventually without regaining the weight The Coles and Woolworths home brand products Leanne and Susie buy every single week without hesitation: rolled oats, canned legumes, passata, frozen vegetables, cottage cheese, Greek yogurt, chicken breast bites, marinated chicken, and more. Specific product names, aisle locations, and honest reasons why Why the Coles Kitchen frozen grilled vegetables and the Woolworths chicken breast bites are non-negotiables in both shopping trolleys, and the specific products in the Coles Perform and Coles Kitchen ranges that keep making it back onto the list The Aldi Gourmet Protein Bar reviewed: 10 grams of protein, 37% nuts and seeds, less than a dollar per bar, and a price-per-protein calculation that puts most supermarket bars to shame. What the ingredient list actually contains and who this bar is genuinely suited to Continuous glucose monitors: who actually needs one, why Leanne and Susie have both turned down paid partnerships with CGM companies, and the specific situations where they might genuinely be useful versus where they are more likely to create unnecessary food fear See omnystudio.com/listener for privacy information.

Everyone's talking about Ozempic. But almost no one tells you what it's quietly doing to your body, or how to use it without paying for it later.Justin Roethlingshoefer breaks down the long-term side effects of GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound (semaglutide and tirzepatide): the muscle and bone you lose, why people quit, what happens when you stop, and the protocol to do it right.This episode isn't anti-GLP-1. For type 2 diabetes, severe obesity, or high cardiovascular risk these drugs can be extraordinary. But in the STEP 1 trial, 40% of the weight lost was lean body mass: for every 10 pounds gone, up to 4 can be muscle.In this episode:

Traveling while taking Ozempic, Wegovy, Mounjaro, or Zepbound? Wondering how to enjoy your vacation without feeling like you're undoing all of your progress?The good news is—you don't have to choose between making memories and staying on track.In this episode, Registered Dietitian, Certified Personal Trainer, Gianna shares her practical, flexible approach to traveling on a GLP-1. From airports and road trips to cruises, all-inclusive resorts, and family vacations, you'll learn how to confidently navigate food, movement, hydration, and your medication—without guilt or perfectionism.Because the goal isn't to have the "perfect" vacation. The goal is to enjoy your trip, take care of yourself, and come home ready to jump back into your routine.In this episode, you'll learn:How to prepare for travel while taking a GLP-1Tips for flying with Ozempic, Wegovy, Mounjaro, or ZepboundEasy, protein-rich travel snacks to packHow to eat at buffets, restaurants, and on vacation without overthinking itWhy movement doesn't have to look like a gym workout while travelingWhat to do if the scale is higher after vacationHow to get back into your routine without guilt, detoxes, or "starting over"Why flexibility is one of the most important skills for long-term successIf you've ever worried about gaining weight on vacation or wondered how to travel while taking a GLP-1 medication, this episode is full of practical strategies you can use on your very next trip.

The rise of GLP-1 medications such as Ozempic, Wegovy and Mounjaro has transformed the treatment of obesity and type 2 diabetes. But as their use rapidly increases, a growing list of potential risks are emerging.So how do GLP-1 drugs work? And what are the potential risks and benefits?

¿Has escuchado maravillas sobre medicamentos como Ozempic, Wegovy o Mounjaro, pero nadie te habla de las constantes náuseas y el malestar estomacal? La realidad clínica es que una gran parte de los pacientes abandonan estos tratamientos para la obesidad simplemente porque los efectos secundarios arruinan su calidad de vida. Pero la ciencia médica está a punto de dar un salto monumental. En este episodio, descubriremos a la AMILINA, una hormona producida por tu páncreas que está demostrando resultados asombrosos en ensayos clínicos: pérdida de peso significativa sin los severos vómitos ni malestares intestinales de los fármacos actuales. En este episodio aprenderás: → Cómo tu páncreas libera dos hormonas cada vez que comes. → Cómo la amilina bloquea el freno metabólico que hace que recuperes el peso perdido. → Cómo dos equipos de investigadores resolvieron el mismo problema químico de formas distintas. → Cómo la combinación CagriSema alcanza una reducción significativa del peso corporal. → Por qué la amilina resensibiliza tu cerebro a la leptina, algo que la semaglutida no logra.   Mi nombre es Dr. Mauricio González, médico internista y especialista en endocrinología en formación. Aquí comparto información basada en evidencia para que tomes decisiones de salud sin mitos ni marketing engañoso. Suscríbete a mi boletín informativo en: www.drmauriciogonzalez.com/   ⚠️ Este podcast tiene fines exclusivamente educativos e informativos y no constituye asesoramiento médico, diagnóstico ni tratamiento personalizado. Los medicamentos que se discuten en este episodio se encuentran en fase de investigación y no cuentan con aprobación de la FDA. Consulta siempre a tu médico o a un profesional de la salud calificado antes de cambiar tu régimen de tratamiento.   ¡Sigamos la conversación en redes sociales! Instagram

GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are everywhere, but are they dangerous shortcuts, life-changing tools, or both?   In this episode of The Body Wisdom Podcast, Jamie Belz, FNTP, MHC, and nutrition expert Kelly Dorfman examine both sides of the GLP-1 debate, including the risks, benefits, and unanswered questions surrounding semaglutide, tirzepatide, weight loss, blood sugar, food noise, and metabolic health.   Kelly Dorfman, M.S., L.D.N., is a leading expert in using therapeutic nutrition to support brain function, energy, and mood. She has appeared on CNN's American Morning and in The Wall Street Journal, O, The Oprah Magazine, and Goop. Her award-winning book, Cure Your Child with Food: The Hidden Connections Between Nutrition and Childhood Ailments, was praised by Publishers Weekly for its "fascinating and potentially life-changing advice."   GLP-1 medications are criticized as an easy button for weight loss. They can cause nausea, vomiting, constipation, dehydration, nutrient deficiencies, muscle loss, bone loss, and other serious side effects. Questions remain about their long-term effects, what happens when someone stops taking them, and whether users may need them for life.   At the same time, GLP-1s are life-changing for some people. They may help those who have spent years battling obesity, insulin resistance, constant hunger, food noise, or a body that will not respond despite consistent effort. These medications may quiet obsessive thoughts about food, reduce overeating, improve metabolic markers, and remove shame from a struggle not always solved by discipline.   So, are GLP-1s really that bad? Or have both sides become too absolute?   Jamie and Kelly explore: • How Ozempic, Wegovy, Mounjaro, Zepbound, semaglutide, and tirzepatide differ • Why appetite, food noise, overeating, and weight are not simply matters of willpower • How GLP-1s affect digestion, blood sugar, inflammation, and reward pathways • Why rapid weight loss can mean losing muscle, collagen, and essential nutrients • The benefits of reducing overeating and improving metabolic health • The risks of digestive problems, dehydration, nutrient deficiencies, and diminished desire • Why protein, fiber, hydration, nutrients, and professional support matter • Whether GLP-1s are temporary tools or lifelong commitments • What may happen when someone stops taking a GLP-1 • How GLP-1s may affect alcohol cravings and other compulsive behaviors • Why foundational health habits still matter • How to make an informed, bio-individual decision without shame, hype, or fear   GLP-1 medications are neither all good nor all bad. For the wrong person, they may create more problems than they solve. For the right person, with the right dose and support, they may be genuinely life-changing.   Jamie encourages listeners to give the Foundations of Health an honest try and seek individualized guidance from a Nutritional Therapy Practitioner.   This episode is for educational purposes only and is not medical advice.   Other Episodes Mentioned: ⁠S2E5 (about protein)⁠ ⁠S1E7 Dehydration Nation⁠ ⁠S1E35 (on childhood obesity)⁠ Find Kelly Dorfman Online at ⁠www.kellydorfman.com⁠. Get Kelly's book:⁠ Cure Your Child with Food: The Hidden Connection Between Nutrition and Childhood Ailments ⁠ Connect with Jamie on Instagram:  ⁠⁠https://www.instagram.com/jamiebelzfntp/⁠⁠⁠⁠ ⁠⁠https://www.instagram.com/stories/thebodywisdompodcast/⁠⁠ Work with a Nutritional Therapy Practitioner (NTP): ⁠⁠NTP in Private Practice⁠⁠ ⁠⁠NTP at NTA Health ⁠⁠  Check out the ⁠Nutritional Therapy Association ⁠⁠⁠ ⁠Join a webinar to see if the Nutritional Therapy Practitioner Program is right for you!⁠ ⁠⁠⁠ Please give The Body Wisdom Podcast a five-star review and share this episode with a friend. THANK YOU!

Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being fought for.In this episode, we break down Novo Nordisk's lawsuit accusing Eli Lilly of misleading patients through advertisements comparing Zepbound and Mounjaro with Wegovy and Ozempic. The fight is not simply about which medication produces more weight loss. It is about who controls the information patients receive, which evidence gets highlighted, and what gets left in the fine print.Then we examine STAT News' investigation into LifeMD, a major telehealth company promoted by Novo as a legitimate pathway to GLP-1 treatment. Former employees alleged providers were pushed to process patients at breakneck speed, sometimes reviewing as many as 25 cases per hour, while refill queues, dose increases and patient messages piled up. LifeMD strongly disputes those allegations.But this cannot become another simplistic story about telehealth being bad.More than 100 million Americans are living with obesity, and only a small number of clinicians have dedicated obesity medicine expertise. The traditional healthcare system does not have enough specialists, appointment slots or geographic reach to provide every patient with an ideal, hour-long consultation.So how altruistic can we afford to be about access?Can we demand a perfect standard of care that most patients will never be able to reach? Or does scaling treatment too aggressively risk turning patients into transactions inside a prescription machine?Access cannot become a shield for negligence. But perfection cannot become another form of gatekeeping.The patient is being fought over. This episode asks what it would actually mean to fight for them.Learn more and follow On The Pen: https://www.otplinks.comThis episode is sponsored by VoaFit, where I receive care for obesity and metabolic health. https://www.voafit.com/otp to learn more!

P.M. Edition for July 21. Recent AI models from China claim they're just as powerful as some of the most cutting-edge models from OpenAI and Anthropic. Journal reporter Amrith Ramkumar joins to discuss the latest reactions from Silicon Valley and the White House. Plus, General Motors had a strong second quarter as consumers kept buying pickup trucks and SUVs. And New Jersey says a software error led to almost 400 non-citizens voting in elections in the state since 2023. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Novo Nordisk files a deceptive advertising lawsuit against Eli Lilly. And the latest Chinese AI model launches rattle expectations for the biggest AI players in the US. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Carl Icahn's company agrees to sell auto-service chain Pep Boys. And Ukraine strikes a deal with defense company BAE Systems to manufacture howitzers locally. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Can you still eat at restaurants while taking Ozempic, Wegovy, Mounjaro, or Zepbound?Absolutely.One of the biggest misconceptions about GLP-1 medications is that you have to avoid restaurants, skip vacations, or order the “healthiest” item on the menu to lose weight. The truth? Long-term success comes from learning how to navigate real life—not avoiding it.In this episode, Registered Dietitian and Certified Personal Trainer, Gianna Beasley shares her simple, evidence-based strategy for eating out while staying true to your health goals. You'll learn how to build balanced meals, listen to your body's fullness cues, and enjoy restaurant meals without guilt, stress, or overthinking every bite.Whether you're headed to date night, a family dinner, a work lunch, or vacation, this episode will help you feel confident ordering at almost any restaurant while taking a GLP-1.In this episode, you'll learn:How to order at restaurants while taking a GLP-1A simple meal-building formula you can use almost anywhereWhy you don't need to avoid eating out to be successfulHow to prioritize protein without obsessing over caloriesWhat to do when you feel full halfway through your mealTips for reducing nausea or digestive discomfort when dining outHow to navigate appetizers, desserts, and drinks without guiltWhat to say when people comment on how much—or how little—you're eatingIf you've ever searched “What should I order on Ozempic?”, “Can I eat at restaurants on Wegovy?”, or “How do I eat out on a GLP-1?”, this episode is for you.

Have you heard of Farxiga (dapagliflozin), Jardiance (empagliflozin), Ozempic, Wegovy, Mounjaro, or finerenone, but aren't quite sure what they do or whether they're right for people living with kidney disease?   In this episode of Diary of a Kidney Warrior Podcast, host Dee Moore is joined by Professor Alex, Consultant Nephrologist and researcher, for an essential conversation about some of the biggest breakthroughs in kidney medicine in recent years.   Originally developed for diabetes, SGLT2 inhibitors have transformed kidney care and are now helping to protect kidney function, reduce protein in the urine and improve outcomes for many people living with chronic kidney disease (CKD). We also explore the growing role of GLP-1 receptor agonists and finerenone, and explain what patients need to know about these treatments.   Whether you're living with chronic kidney disease, caring for someone who is, or you're a healthcare professional wanting a patient-friendly explanation, this episode is packed with practical, evidence-based information.   In this episode, you'll learn:   ✅ What SGLT2 inhibitors are and how they protect the kidneys ✅ Why medications developed for diabetes are now transforming kidney care ✅ How GLP-1 receptor agonists (including Ozempic, Wegovy and Mounjaro) may benefit kidney health ✅ What finerenone is and who may benefit from it ✅ Why your eGFR may temporarily fall after starting treatment—and why this isn't always a cause for concern ✅ The benefits and possible side effects of these medications ✅ Which kidney patients may be suitable for these treatments ✅ The latest developments in kidney research and future treatments   This episode shares expert insight designed to educate, empower and inspire people living with kidney disease and those who support them.  

L'internet adore les explications simples sur l'obésité. Mangez moins, bougez plus, faites preuve de volonté. Dans cet épisode, un chirurgien bariatrique et une psychologue clinicienne expliquent pourquoi cette vision ne tient pas compte de la réalité humaine ni de la biologie. Si vous vous êtes déjà senti jugé en raison de votre poids, ou si vous vous êtes déjà reproché d'avoir repris du poids, cette conversation remplace la culpabilité par la science.Nous abordons l'obésité comme une maladie chronique influencée par la génétique, les hormones, le métabolisme, les médicaments, le stress, les mécanismes d'adaptation et un environnement rempli d'aliments peu coûteux et hyperappétents. Vous découvrirez que les interventions comme la gastrectomie en manchon et le pontage gastrique font bien plus que réduire la taille de l'estomac. Elles modifient aussi les hormones de la faim et de la satiété, notamment la ghréline et le GLP, tout en permettant de mieux comprendre des concepts comme la théorie du point d'équilibre pondéral, ainsi que les raisons pour lesquelles le corps résiste souvent à une perte de poids durable.Nous discutons également des aspects psychologiques de l'obésité, notamment l'alimentation émotionnelle, le bruit alimentaire, la stigmatisation liée au poids, les changements d'identité après la chirurgie et les raisons pour lesquelles mesurer le succès uniquement avec le chiffre sur la balance peut devenir contre-productif. Vous découvrirez aussi des stratégies concrètes, comme prioriser les protéines et les fibres pour favoriser la satiété et réduire la faim, ainsi que des approches réalistes pour bâtir des habitudes durables.Enfin, nous parlons des médicaments agonistes du GLP, 1, comme Wegovy, Ozempic, Mounjaro et Zepbound. Nous expliquons leur rôle dans le traitement de l'obésité, pourquoi ils sont souvent mal compris et pourquoi les meilleurs résultats sont obtenus lorsqu'ils sont combinés à des changements durables des habitudes de vie et à un suivi régulier.Si cette conversation vous a été utile, abonnez-vous, laissez un avis et partagez cet épisode avec une personne qui pourrait bénéficier d'une vision plus compatissante et fondée sur les données scientifiques de l'obésité.Go check out my website for tons of free resources on how to transition towards a healthier diet and lifestyle.You can download my free plant-based recipes eBook and a ton of other free resources by visiting  the Digital Downloads tab of my website at https://www.plantbaseddrjules.com/shopDon't forget to check out my blog at https://www.plantbaseddrjules.com/blog You can also watch my educational videos on YouTube at https://www.youtube.com/channel/UCMpkQRXb7G-StAotV0dmahQCheck out my upcoming live events and free eCourse, where you'll learn more about how to create delicious plant-based recipes: https://www.plantbaseddrjules.com/Go follow me on social media by visiting my Facebook page and Instagram accountshttps://www.facebook.com/plantbaseddrjuleshttps://www.instagram.com/plantbased_dr_jules/Last but not least, the best way to show your support and to help me spread my message is to subscribe to my podcast and to leave a 5 star review on Apple and Spotify!Thanks so much!Peace, love, plants!Dr. Jules 

Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing. Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule. She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels. Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157 Go Beyond The Podcast Join Chalene on her private podcast

Ozempic is helping millions lose weight—but what if it's also causing a hidden form of muscle loss most people never see coming?"Ozempic feet" has become a viral term, but the real concern isn't just how your feet look—it's what rapid weight loss may be doing to your muscle mass, strength, metabolism, and long-term health.In this eye-opening episode of Accelerated Health with Sara Banta, I uncover the truth behind Ozempic muscle loss, why it happens, who is most at risk, and the science-backed strategies to rebuild lean muscle while protecting your health.If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication—or considering one—this is information you need before your next step.Supplements Featured In This Episode:• Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care • Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast®  https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement • Accelerated Ancient Salt® https://www.acceleratedhealthproducts.com/products/accelerated-ancient-salt-4-oz Not sure what food to eat and avoid? This guide is for you.⬇️

Few prescription drugs have generated as much excitement as the new generation of weight-loss drugs, commonly called “GLP-1” medications. You've probably heard about Ozempic, Wegovy, Zepbound, and Mounjaro, even if you don't want to lose weight.In this episode: How do these drugs work? How to deal with the sometimes-unpleasant side effects? What has the GLP-1 family of drugs been proven to do, and what could they be used for in the future? Plus, details about a new Medicare program that now covers these drugs when prescribed for weight loss for those who qualify.Not a Checkbook member? ⁠⁠⁠⁠⁠⁠Sign up for a free 30-day trial to access all of our unbiased ratings⁠⁠⁠⁠⁠⁠.

Uno de cada diez adultos en Estados Unidos utiliza ya un fármaco inyectable para perder peso y su uso no deja de crecer en Europa. El auge de medicamentos como Mounjaro y Ozempic está transformando la industria farmacéutica y cambiando la forma de abordar la obesidad. En Hora 25 de los Negocios conversamos con el CEO de Eli Lilly en España sobre el futuro del sector y el momento que vive la compañía, que acaba de convertirse en la primera farmacéutica del mundo en alcanzar el billón de dólares de valor en bolsa.

Uno de cada diez adultos en Estados Unidos utiliza ya un fármaco inyectable para perder peso y su uso no deja de crecer en Europa. El auge de medicamentos como Mounjaro y Ozempic está transformando la industria farmacéutica y cambiando la forma de abordar la obesidad. En Hora 25 de los Negocios conversamos con el CEO de Eli Lilly en España sobre el futuro del sector y el momento que vive la compañía, que acaba de convertirse en la primera farmacéutica del mundo en alcanzar el billón de dólares de valor en bolsa.

Has your weight loss suddenly stopped on Ozempic, Wegovy, Mounjaro, or Zepbound?If the scale hasn't moved in weeks and you're wondering whether your GLP-1 has stopped working, you're not alone. Weight loss plateaus are one of the most common—and frustrating—parts of the GLP-1 journey.The good news? A plateau doesn't automatically mean you've done something wrong or that your medication has failed.In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 expert Gianna explains why weight loss plateaus happen, what your body is actually doing, and the evidence-based questions she asks clients before making any changes.We'll cover:What actually counts as a weight loss plateauWhy weight loss naturally slows over timeThe difference between normal weight fluctuations and a true stallCommon reasons GLP-1 weight loss plateaus happenHow protein, hydration, fiber, sleep, stress, and movement influence progressWhy eating less isn't always the answerWhen it may be time to talk with your healthcare providerThe mindset shift that helps you move through a plateau without panicIf you've been asking yourself, “Why did my weight loss stop on Ozempic?” or “Why isn't my GLP-1 working anymore?” this episode will help you understand what may be happening and what to focus on next.

¿Son los nuevos fármacos para perder peso la solución definitiva o una trampa con fecha de caducidad? En el caso real de hoy analizamos la historia de una paciente de 45 años, con un cargo directivo de alta responsabilidad y altos niveles de estrés, que decidió pincharse Mounjaro buscando una vía rápida para adelgazar antes de un evento. Soportó meses de náuseas constantes, vómitos semanales y reflujo severo bajo la falsa creencia de que "si dolía y sufría, es que estaba funcionando". Tras suspender el tratamiento por intolerancia gástrica, el hambre voraz regresó, provocando un durísimo efecto rebote en el que recuperó todo lo perdido más 6 kilos de regalo. Descubre cómo abordamos en consulta este caso para reparar su metabolismo, sanar su relación con la comida y devolverle la libertad mental.En este episodio aprenderás:Por qué fármacos como Mounjaro u Ozempic actúan como un "tapón" temporal pero no solucionan los problemas de base si no hay reeducación nutricional.El peligro oculto de la pérdida drástica de masa muscular y cómo esto destruye y ralentiza tu metabolismo.Herramientas de psiconutrición para reaprender a escuchar las señales reales de hambre y saciedad tras una supresión artificial del apetito.Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/comiendo-con-maria-nutricion--2497272/support.

Today we're tackling one of the hottest topics in medicine, nutrition, and weight loss. GLP-1 medications.You know them by names like Ozempic, Wegovy, Mounjaro, and Zepbound. You've seen the commercials.You've heard the celebrity stories. You probably know someone taking one. Maybe you're taking one yourself.These medications have transformed the conversation around weight loss, and for many people they have been life-changing. But they've also raised some important questions. Can we naturally stimulate our own GLP-1? And now, Can fasting provide some of the same benefits?And is the future of weight management medication, lifestyle, or a combination of both? Fasting & GLP-1

Los tratamientos con agonistas GLP-1 han supuesto un antes y un después en el manejo de la obesidad. Pero, como ocurre con cualquier herramienta terapéutica, no todo consiste en perder peso y, aunque estos fármacos ofrecen muy buenos resultados, también conllevan una gran responsabilidad: evitar perder salud metabólica por el camino.Porque, ¿qué pasa con el músculo? ¿Por qué es tan importante asegurar un adecuado consumo de proteínas? ¿Qué papel juega la fibra cuando comemos menos? ¿Y qué micronutrientes conviene vigilar, como el hierro, la vitamina B12, la vitamina B1, vitamina D o la colina?En este episodio hablamos de la parte del tratamiento de la que menos se habla: cómo conseguir que la pérdida de peso sea, además, una pérdida de grasa… y no de salud. Porque adelgazar no debería significar perder fuerza, funcionalidad ni aumentar el riesgo de déficits nutricionales.Si tú o alguien cercano está siguiendo un tratamiento con un agonista GLP-1, creo que este episodio puede ayudaros a entender cómo acompañarlo desde la fisiología y la evidencia científica para obtener los mejores resultados.Y si, además, quieres profundizar en otros aspectos relacionados con estos tratamientos, te recomiendo escuchar también los episodios 77 y 111, donde encontrarás información complementaria que te ayudará a entender mejor su funcionamiento, sus beneficios y cómo utilizarlos de la forma más segura y eficaz posible.Como siempre digo: saber más para temer menos y elegir mejor.Para mas información ya sabéis que me tenéis en mi instagram @isabelvina dónde te comparto contenido diario Mi TikTok @isabelvinabasEn mi canal de YouTube Canal YoutubeY los suplementos formulados por mi en mi web  Mi web

In the western world, richer people tend to be thinner – especially women. But does wealth make people thin, or does being thin make them wealthy? And could the rise of weight-loss drugs such as Mounjaro and Wegovy give people – especially women – greater control over their economic outcomes? Soumaya speaks to Harvard professor Rebecca Diamond, the author of a new working paper that finds female users of GLP-1 drugs are more likely to find jobs and romantic partners. Soumaya also speaks to FT consumer editor (and GLP-1 user) Claer Barrett to discuss the drugs' effects on consumer habits – and the economy at large.Subscribe to Soumaya's show on Apple, Spotify, Pocket Casts or wherever you listen.Further reading: The economics of women's weightDoes the weight-loss revolution show up in the data?The challenges of a weight-loss economyPresented by Soumaya Keynes. Produced by Mischa Frankl-Duval. Original music and sound design by Breen Turner. Andrew Georgiades is the broadcast engineer. Manuela Saragosa is the executive producer. Flo Phillips if the FT's head of audio.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Is Ozempic secretly slowing down your thyroid? Millions are using GLP-1 medications like Ozempic for weight loss and blood sugar control, but very few people are being warned about what they could be doing to their thyroid health.If you're experiencing fatigue, hair loss, brain fog, cold hands and feet, constipation, or stubborn weight loss plateaus after starting Ozempic, your thyroid may be sending you warning signs that are often overlooked.In this eye-opening episode of Accelerated Health with Sara Banta, I uncover the surprising connection between Ozempic, GLP-1 medications, and thyroid function, why standard thyroid testing may miss the problem, and the essential nutrients your thyroid needs to function properly.If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication, this is information you don't want to miss.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement Not sure what food to eat and avoid? This guide is for you.⬇️

Have you ever looked in the mirror and wondered, "Why is it so much harder to lose weight than it used to be?" Maybe you've tried the diets... counted the calories... exercised faithfully... only to watch the scale refuse to budge. What if the problem isn't a lack of willpower? What if we've been asking the wrong question all along?Today on Call IT in With Dar, I'm joined by Dr. William Summers, a physician with more than 36 years of experience helping people understand the science behind obesity. As a board-certified OB/GYN and medical weight management specialist, Dr. Summers believes it's time we stop blaming ourselves and start recognizing obesity for what it truly is—a complex medical condition influenced by biology, hormones, metabolism, and our modern environment.  In this myth-busting conversation, we'll explore why obesity has become one of the greatest health challenges of our time, what new research is revealing, how medications like Ozempic and Mounjaro are changing the conversation, and most importantly, why compassion and understanding are far more powerful than guilt and shame.  Whether you're struggling with your own weight, supporting someone you love, or simply wanting to separate fact from fiction, this episode offers clarity, hope, and practical insight.  Let's come together for this important conversation about obesity! Call It in with Dar! Support the showFull Show Notes can be found at CallITInPodcast.comPhoto credit: Rebecca Lange Photography Music credit: Kevin MacLeod Incompetech.com (licensed under Creative Commons)  Production credit: Erin Schenke @ Emerald Support Services LLC.Grab Dar's Flight Deck Oracle Card DeckTake Dar's Archetype Quiz

Have you ever looked at your life and weight loss journey and felt like nothing is changing?Like one workout doesn't matter. One healthy meal won't make a difference. One act of self-care feels insignificant. In this episode, I'm sharing one of my favorite metaphors: diamond painting.Each tiny diamond seems insignificant on its own. You can't see the finished picture while you're placing them. But over time, those thousands of tiny pieces become something beautiful.The same is true for healing your relationship with food, building confidence, embracing your body, becoming the woman you crave to be, and creating the irresistible life you deserve. If you've been judging yourself before you've had the chance to see the full picture, this episode is your reminder to trust the process.Because you're not just placing diamonds.You're building an irresistible life—one tiny diamond at a time.Irresistible Links:Show Notes

In this episode, I'm talking about why so many attempts to change your relationship with food seem to fizzle out, even when you're motivated and genuinely want things to be different. Because constantly starting over doesn't mean you're lazy, uncommitted, or missing some magical piece of information. We're digging into the deeper reasons certain behaviors stick around, what they may actually be doing for you, and why curiosity is often far more helpful than criticism.  This conversation goes beyond meal plans and motivation and gets into the questions that most people never think to ask. Quotes "We don't lead with the question, what do we do about this? We lead with the question, what is this actually all about? It's the question that changes everything when someone is really willing to look at it, because the answer is usually not what you think it is." "Most of us are so focused on fixing the behavior that we haven't stopped to ask what the behavior is doing." "The reason change feels so hard isn't because you're weak; it's because something would have to be given up if you changed. Meaning, if the behavior is protective in some way, shape, or form, it's providing something for you." "You don't need to know the answer yet. The key is starting to think about this and removing the blame that we're pointing at ourselves and starting to ask questions." "Sometimes this isn't something that you can do alone, and that's where you might need a real person like a therapist or a dietician. Sometimes we need people who can see the patterns that we're too close to see." Frequently Asked Questions Why do I keep failing when I try to change my eating habits? Repeatedly struggling with food does not necessarily mean you lack motivation or discipline. Many behaviors serve a purpose, and understanding what they are providing can help create lasting change.   Why do I sabotage myself around food? What feels like self-sabotage is often a protective pattern. Behaviors around food may be helping you cope with emotions, stress, shame, or fear, even when those behaviors are no longer serving you well.   Why is giving up dieting so scary? For many people, dieting feels tied to safety, control, belonging, or fear of weight gain. Letting go of those rules can bring up emotions and beliefs that deserve attention and support.   What does fear of weight gain really mean? Fear of weight gain often goes beyond the number on the scale. It can be connected to shame, past experiences, fears of rejection, or beliefs about worth and acceptance.   Why do I feel stuck between wanting recovery and wanting to stay the same? Feeling pulled in two directions is called ambivalence, and it is a normal part of recovery. Having conflicting feelings does not mean you're doing anything wrong.   Does structured eating help with disordered eating? Structured eating provides consistency and helps create a foundation for healing. Many people benefit from eating regularly throughout the day rather than relying on hunger cues alone in the early stages of recovery.   Do I need a therapist or a dietitian for eating disorder recovery? Support can be helpful when you're too close to your own patterns to see them clearly. A therapist or dietitian can help you understand what is driving your behaviors and provide practical tools for recovery. Resources Be sure to sign up for my weekly newsletter! Brave on Purpose! - Grab my new book here! Grab my Journal Prompts Here! Looking for a speaker for an upcoming event? Let's chat! Now accepting new clients! Find out if we're a good fit!    Episodes Mentioned: -Episode 45. Basics of Intuitive Eating -Episode 122. Ozempic, Wegovy, & Mounjaro with Laura Cipullo -Episode 133. GLP with Dr. Kim Dennis -Episode 160. Intuitive Eating Updates You Need to Know with Elyse Resch MS, RDN, CEDS-C, Fiaedp, FADA, FAND   LEAVE A REVIEW + help someone who may need this podcast by sharing this episode. Be sure to sign up for my weekly newsletter here! You can connect with me on Instagram @rachelleheinemann, through my website www.rachelleheinemann.com, or email me directly at rachelle@rachelleheinemann.com

Thought your GLP-1 medication would completely eliminate sugar cravings?If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound and still find yourself craving chocolate, sweets, chips, or your favorite snacks, you're definitely not alone.The truth is, cravings are much more complex than most people realize—and having cravings doesn't automatically mean your medication has stopped working.In this episode, Registered Dietitian and Certified Personal Trainer, Gianna breaks down the science behind food cravings, explains why they can still happen while taking a GLP-1, and shares practical, evidence-based strategies to help you better understand what your body may be trying to tell you.We'll cover:Why you may still crave sugar while taking a GLP-1The difference between hunger, cravings, and food noiseHow under-eating can actually increase cravingsWhy protein matters—but isn't the entire solutionThe impact of sleep, stress, and daily habits on cravingsWhy emotional eating can still happen on a GLP-1How years of habit can influence what you craveWhen cravings may be worth discussing with your healthcare providerIf you've ever wondered, “Why am I still craving sugar on Ozempic?” or worried that cravings mean your medication has stopped working, this episode will help you understand what's actually happening—and how to respond with curiosity instead of guilt.

GLP-1 receptor agonists have become some of the most talked-about medications in recent years. You may have heard names such as liraglutide, semaglutide (Ozempic and Wegovy), and tirzepatide (Mounjaro). These treatments have attracted attention because they can significantly reduce appetite and support weight loss while also helping to manage blood glucose levels. The breakthrough came when researchers developed long-acting versions of hormones naturally released by the body after eating, including GLP-1 and, in some cases, GIP. These hormones help regulate hunger and promote feelings of fullness. While the body's natural response lasts only a short time, modern medications extend these effects for up to a week with a single injection. Since results from major clinical trials emerged in the early 2020s, GLP-1 therapies have transformed obesity treatment, delivering weight-loss outcomes that surpass those achieved by previous medications and offering new hope for people struggling with weight management. - Laureate Professor Clare Collins, internationally distinguished leader in nutrition and dietetics, University of NewcastleSee omnystudio.com/listener for privacy information.

What if the biggest challenge isn't losing the weight... but keeping it off after Ozempic?Millions of people have turned to GLP-1 medications like Ozempic, Wegovy, and Mounjaro for life-changing weight loss. But what happens when you stop taking them? For many, the weight starts coming back faster than expected.In this episode of Accelerated Health with Sara Banta, I break down the science behind weight regain after GLP-1 medications and reveal practical strategies to help you transition off these drugs while supporting a healthy metabolism.Whether you're currently taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication—or you're thinking about stopping—this episode provides valuable insights to help you make informed decisions alongside your healthcare provider.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast® https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement • Accelerated Ancient Salt® https://www.acceleratedhealthproducts.com/products/accelerated-ancient-salt-4-oz Not sure what food to eat and avoid? This guide is for you.⬇️

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

Resources for the Community:___________________________________________________________________Linktree Our Favorite ThingsNeed help appealing your GLP-1 dials? www.FindHonestCare.com/KimFind Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Can GLP-1s Affect Food Noise, Alcohol, and Addiction?** While Kim takes time away following the passing of her sister, we're revisiting some of our most impactful conversations. Thank you for your kindness, patience, and continued support of The Plus SideZ Podcast.We're sharing this episode because it's more relevant today than when it first aired. Since then, research has expanded interest in whether GLP-1 medications may affect more than weight loss, including food noise, alcohol cravings, and other compulsive behaviors. While the science continues to evolve, so does the conversation.Licensed therapist and addiction treatment leader Dr. Joy Bracey joins community member Brenda, who shares how Mounjaro changed her relationship with food, alcohol, and smoking. Together, they discuss the brain, behavior, and why this emerging area of research is drawing growing interest.**In this episode:**• Brenda's journey with obesity, binge eating, alcohol, smoking, and Mounjaro• Food noise, binge eating, and emotional eating• GLP-1 medications, dopamine, and the brain• Alcohol cravings and addictive behaviors• Mental health, self-love, and healing• Why researchers are studying GLP-1 medications beyond weight loss*Originally recorded during Season 1. This episode reflects the information available at the time of recording. Research and clinical guidance have continued to evolve. It is intended for education and discussion only and is not medical advice. Always consult your healthcare provider regarding your individual care.*______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #RealGLP1StoriesSend us Fan Mail!Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

Started feeling hungry again on your GLP-1 and wondering if your medication has stopped working?You're not alone.One of the biggest misconceptions about Ozempic, Wegovy, Mounjaro, and Zepbound is that you should never feel hungry. But the truth is, hunger is a normal biological signal—and experiencing hunger doesn't automatically mean your GLP-1 isn't working.In this episode, Registered Dietitian and GLP-1 expert Gianna explains why appetite can change throughout your GLP-1 journey, what influences hunger beyond your medication, and how to tell the difference between normal hunger and something that may deserve a conversation with your healthcare provider.We'll discuss:Why it's normal to feel hungry on a GLP-1Whether your medication can “stop working”The difference between hunger and food noiseCommon reasons your appetite may increaseHow under-eating can actually make hunger worseThe impact of stress, sleep, hormones, and daily routines on appetiteWhen increased hunger may be a reason to talk with your healthcare providerWhy learning to trust your body's hunger cues is part of long-term successIf you've ever worried that feeling hungry means you've failed—or that your medication isn't doing its job—this episode will help you understand what's actually happening and how to respond with confidence instead of fear.

Dr. David Healy, psychiatrist, psychopharmacologist, and author of Pharmageddon, returns to lay out what he argues the drug companies concealed about antidepressants. He says the healthy-volunteer trials showed sexual side effects in close to 90% of people while the marketed figure was under 5%, and he explains why he considers the word "antidepressant" itself a marketing term. Host Mike Vera, MS, NBC-HWC, walks through the trial data, informed consent, and whether the same pattern is now repeating with GLP-1 drugs. This is a discussion of Dr. Healy's research and perspective, shared for educational purposes only, and it is not medical advice.A note before you listen: this conversation covers antidepressants, SSRIs, and mental health, including the subject of suicidal thoughts. It is not a recommendation to start, stop, or change any medication. Always make medication decisions with your prescribing clinician. If you are struggling or in crisis, support is available 24/7: in the US, call or text 988 (Suicide and Crisis Lifeline), or text HOME to 741741 (Crisis Text Line). Outside the US, contact your local emergency services or crisis line.

De kilo's vliegen eraf bij mensen die afvallen met middelen als Ozempic, Mounjaro en Wegovy. Door de spuiten te zetten heb je minder honger en val je af. Maar mensen die het gebruiken zeggen ook andere dingen te merken. Zo zouden ze ook effect hebben op hart en vaten, op slaapapneu en zelfs kunnen helpen voor hiv-patienten. Online gaan mensen nog verder: bijvoorbeeld ook migraine zou verholpen worden door middelen als Ozempic. Die bijvangst van het medicijn fascineerde Nieuwsuur-verslaggever Lune van der Meulen en ze dook deze week in de afvalrevolutie die gaande is. Het grappige is dat afvallen een bijvangst was van deze middelen, want ze zijn eigenlijk ontwikkeld voor diabetes. Welke bijvangst die nu wordt opgemerkt is wetenschappelijk aangetoond? En wat betekent dat voor het potentieel van deze afvalmedicijnen? In de serie is naast deze bijvangst ook aandacht besteed aan stoppen met afvalmedicatie (https://nos.nl/nieuwsuur/video/2620128-stoppen-met-afslankmedicijnen-en-dan) en de eisen voordat je mag beginnen (https://nos.nl/nieuwsuur/video/2619839-afslankmedicijn-ultiem-wondermiddel) die veel mensen omzeilen. Reageren? Mail naar dedag@nos.nl (mailto:dedag@nos.nl) Presentatie & montage: Marco Geijtenbeek Redactie: Rosanne Sies

In this podcast, Jennifer Green, MD, and Jay H. Shubrook, DO, FAAFP, FACOFP, share strategies for integrating incretin-based therapies in type 2 diabetes (T2D) management in the primary care setting, including: Importance of moving beyond a glucose-centric approach to T2D care  Current evidence for incretin-based therapies in T2D Rationale for integrating these therapies into the primary care setting Shared decision-making strategies to discuss optimal T2D treatment options with patients Timing for endocrinology referral Presenters: Jennifer Green, MD Professor of Medicine Division of Endocrinology Duke Clinical Research Institute Duke University School of Medicine Durham, North Carolina Jay H. Shubrook, DO, FAAFP, FACOFP Professor, Diabetologist Department of Clinical Sciences and Community Medicine Touro University California, College of Osteopathic Medicine Vallejo, California Full program link: https://bit.ly/4uSKCqv Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why aren't there more medical insurance plans that cover alternative medicine? Solutions for Long Covid; MK7 vitamin K slows arterial calcification; Keto diet shows promise for treatment of anorexia; It's not so much salt restriction—it's the dietary sodium/potassium ratio in hypertension; Study finds multivitamins don't keep you from getting Covid—but when you get it, it's milder; Incidence of social anxiety disorder is soaring among young people.

If I could go back and start my GLP-1 journey all over again, there are a lot of things I would do differently.Not because I regret taking a GLP-1—but because there were lessons I had to learn through experience that I wish someone had told me from the very beginning.In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 user Gianna Beasley shares the biggest things she wishes she knew before starting Ozempic, Wegovy, Mounjaro, and GLP-1 medications, including the nutrition, mindset, and lifestyle lessons that made the biggest difference.We're covering:The mistakes I made early in my GLP-1 journeyWhy protein matters more than most people realizeThe importance of hydration and side effect managementWhy I wish I focused less on the scale and more on strengthThe mental health and mindset work I wish I had done soonerWhy comparison is one of the fastest ways to sabotage your progressWhat actually matters for long-term success on a GLP-1The advice I would give myself if I were starting over todayWhether you're considering a GLP-1, just getting started, or have been taking one for a while, this episode will help you avoid common pitfalls and focus on what truly supports your health and success.

A few years ago, I came across a quote that said:"I think the key to a happy life as an adult woman is to channel your inner weird little girl and make her happy."It immediately resonated with me.I was the kid making potions in the yard, obsessed with magic books, fortune tellers, mood rings, crystals, and all things mystical. And the older I get, the more I realize those parts of me never disappeared—they just got buried under adulthood and responsibility.In this episode, I'm talking about whimsy—not as a trend, but as a way of reconnecting with yourself. I'm sharing what's on my whimsical summer list, why I've been intentionally making more room for wonder, and how this connects to one of the core principles of Irresistible You: Feed Your Soul.Because maybe creating a magical life isn't about becoming someone new.Maybe it's about remembering who you've been all along. ✨

Ozempic, Wegovy and Mounjaro can help people lose weight. But what should you eat on GLP-1 drugs to avoid side effects, protect muscle, and maintain results long term? In this episode, Dr Federica Amati, ZOE's Head Nutritionist and author of The Appetite Reset, explains how these drugs work, why many people struggle with side effects, and why losing weight does not automatically mean better health. You'll learn why the weight lost may not be fat, why nutrient deficiencies, dehydration and muscle loss can become a risk, and what to eat before, during and after treatment. Federica shares four practical principles to help reduce side effects, protect lean mass, improve diet quality and support long-term health whether you stay on these medications or eventually stop taking them. Millions of people are now using GLP-1 drugs. But if these medications reduce appetite so effectively, how do you make sure your body still gets the nutrients it needs?

Misdiagnosed with Type 2 in her 40s, Claire went into DKA while taking Mounjaro and discovered she actually has Type 1 (LADA). Hear her UK healthcare journey. ABLEnow save for today's needs or invest for tomorrow Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 20% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

President Trump uses a wide-ranging White House cabinet meeting to tout his administration's record, press Iran to make a deal, address energy concerns, and respond to the latest security scare near the White House. Former Attorney General Pam Bondi reveals she is being treated for thyroid cancer as Axios reports she is returning to the Trump administration as a liaison on the president's science and technology advisory council. A new Cleveland Clinic study finds GLP-1 drugs like Ozempic and Mounjaro are associated with slower progression in several major cancers, though researchers caution the findings do not prove the drugs caused the improved outcomes. NASA announces a new round of lunar missions and private-sector contracts aimed at testing the landers, vehicles, cargo systems, and survival infrastructure needed to return astronauts to the Moon and eventually reach Mars.   SelectQuote: Compare top‑rated life insurance options. Visit https://SelectQuote.com/megyn to get the right coverage at the right price.   Cozy Earth: This Memorial Day, visit https://www.CozyEarth.com & Use code MEGYN for up to 30% off Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How did Ozempic, Prozac, & Viagra get their names?... It's the wild world of drug-naming.Now is the perfect time to ask your landlord to cut your rent… We got the receipts & playbook.Google's Search Bar is history's most profitable feature… But last week it got plastic surgery.Plus, the hot new vacation trend is lights-off… Dark Sky Vacations have never been brighter.$GOOG $NVO $MARNEWSLETTER:https://tboypod.com/newsletter OUR 2ND SHOW:Want more business storytelling from us? Check our weekly deepdive show, The Best Idea Yet: The untold origin story of the products you're obsessed with. Listen for free to The Best Idea Yet: https://wondery.com/links/the-best-idea-yet/NEW LISTENERSFill out our 2 minute survey: https://qualtricsxm88y5r986q.qualtrics.com/jfe/form/SV_dp1FDYiJgt6lHy6GET ON THE POD: Submit a shoutout or fact: https://tboypod.com/shoutouts SOCIALS:Instagram: https://www.instagram.com/tboypod TikTok: https://www.tiktok.com/@tboypodYouTube: https://www.youtube.com/@tboypod Linkedin (Nick): https://www.linkedin.com/in/nicolas-martell/Linkedin (Jack): https://www.linkedin.com/in/jack-crivici-kramer/Anything else: https://tboypod.com/ About Us: The daily pop-biz news show making today's top stories your business. Formerly known as Robinhood Snacks, The Best One Yet is hosted by Jack Crivici-Kramer & Nick Martell. Hosted on Acast. See acast.com/privacy for more information.